Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. Current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. Organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. These patient-derived models facilitate improved drug sensitivity testing, leading to more personalized treatment plans. In this study, 90 patients diagnosed with metastatic breast cancer accompanied by hydrothorax and ascitic fluid will be recruited. Patient-derived organoids will be used to assess the sensitivity of chemotherapy regimens, including Doxorubicin, Carboplatin, Cyclophosphamide, and Paclitaxel, along with targeted therapies such as Herceptin and Pertuzumab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana świadoma zgoda na uczestnictwo w badaniu.
- •Wiek od 18 do 70 lat.
- •Zaawansowany rak piersi z płynem w płucach i brzuchu zawierającym komórki nowotworu (potwierdzone badaniem).
- •Ogólny stan zdrowia oceniony na 0-1 w skali ECOG.
- •Prawidłowa funkcja wątroby i nerek (bilirubina <1,5× normy; transaminazy <2,5× normy; kreatynina ≤ norma).
✗ Disqualifies
- •Pacjenci niezdatni do chemioterapii i terapii celowanej.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- January 7, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Second affiliated hospital of zhejiang university
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, China
Trial contact
ZHIGANG CHEN, MD
JIAN HUANG, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.